We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Teijin Pharma

News List

Jolly Good and Teijin Pharma Form a Partnership to Develop VR Digital Therapeutics for Depression prnasia
April 25, 2021
Jolly Good Inc. and Teijin Pharma Ltd. have signed a business partnership agreement to develop VR digital therapeutics for Major Depressive Disorder (MDD).
Takeda sells Japan’s non-core products portfolio to Teijin Pharma pharmaceutical-technology
April 02, 2021
Takeda Pharmaceutical has completed the asset transfer linked to a portfolio of select non-core products in Japan to Teijin Pharma for $1.25bn (JPY133bn).
Takeda to sell diabetes products portfolio to Teijin Pharma for $1.25bn pharmaceutical-technology
March 02, 2021
Takeda Pharmaceutical Company has signed an agreement to sell four non-core type 2 diabetes products in Japan to Teijin Pharma for JPY133bn ($1.25bn).
Teijin Pharma and TransThera Biosciences Form Strategic R&D Collaboration prnasia
December 21, 2020
Teijin Pharma Limited, the core company of the Teijin Group's healthcare business headquartered in Tokyo, Japan, and TransThera Biosciences Co. Ltd., a clinical-stage biotechnology company based in Nanjing, China, jointly announced that they have ...